12:00 AM
 | 
Oct 25, 2010
 |  BC Week In Review  |  Company News  |  Deals

Paion, Lundbeck deal

H. Lundbeck and Paion added second-generation and potential follow-on compounds to an amended 2005 deal granting Lundbeck exclusive, worldwide rights to develop and commercialize desmoteplase (DPSA). The original deal was expanded in 2008 to include exclusive,...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >